Navigation Links
XTENT to Retain Investment Bank to Pursue Strategic Alternatives
Date:1/23/2009

MENLO PARK, Calif., Jan. 23 /PRNewswire-FirstCall/ -- XTENT, Inc. (Nasdaq: XTNT) today announced that it plans to engage an investment bank to help the company pursue strategic alternatives which may include the sale of some or all of the company's assets or other types of merger or acquisition transactions intended to maximize shareholder value.

"Given the continued challenges faced in the capital markets, we believe it is in the best interests of the shareholders to consider strategic options," said Gregory D. Casciaro, XTENT's President and CEO. "We remain confident in the benefits of customizable stenting and are assessing all viable options available to us in order to maximize the value of our assets. Effective immediately, we are executing plans to reduce activities and costs to a critical minimum, including a significant reduction in headcount in order to preserve cash and flexibility."

On January 22, 2009, the company notified 112 employees out of its total employment base of 121 employees that their positions would be eliminated effective March 23, 2009.

The company does not intend to disclose developments with respect to its evaluation of strategic alternatives unless and until the evaluation of all proposals and alternatives has been completed and the company has entered into a transaction. There can be no assurances that the company will be able to obtain financing and/or enter into a strategic transaction, or as to the timing or terms of any such transaction.

About XTENT

XTENT, Inc. is a medical device company focused on developing and commercializing innovative customizable drug eluting stent (DES) systems for the treatment of coronary artery disease (CAD). CAD is the most common form of cardiovascular disease and the number one cause of death in the United States and Europe. XTENT(R) Custom NX(R) DES Systems are designed to enable the treatment of single lesions, long lesions and multiple lesions of varying lengths and diameters, in one or more arteries with a single device.

Forward Looking Statements

This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Statements in this press release regarding XTENT's business that are not historical facts may be "forward-looking statements" that involve risks and uncertainties. Specifically, these statements include, but are not limited to those concerning: XTENT's ability to reduce its costs or the timing of such reductions, XTENT's ability to maximize the value of its assets or the timing thereof, XTENT's ability to engage suitable advisors, XTENT's ABILITY TO SUCCESSFULLY IMPLEMENT A STRATEGIC ALTERNATIVE, THE DECISION BY XTENT TO EXPLORE ONE OR MORE STRATEGIC ALTERNATIVES, WHETHER THE STRATEGIC ALTERNATIVES COULD RESULT IN MAXIMIZING SHAREHOLDER VALUE, WHETHER THE ENGAGEMENT OF ADVISORS WILL RESULT IN A STRATEGIC ALTERNATIVE PURSUED OR EFFECTED BY XTENT, AND OTHER RISKS. Forward-looking statements are based on management's current, preliminary expectations, and are subject to risks and uncertainties that could cause actual results to differ from the results predicted and which are included in the "Risk Factors" section of XTENT's most recent quarterly report on Form 10-Q for the quarter ended September 30, 2008. This quarterly report was filed with the SEC on November 12, 2008, and is available on the company's investor relations website at http://www.xtentinc.com and on the SEC's website at http://www.sec.gov. Undue reliance should not be placed on forward-looking statements, which speak only as of the date they are made. XTENT undertakes no obligation to update publicly any forward-looking statements to reflect new information, events or circumstances after the date they were made, or to reflect the occurrence of unanticipated events.

http://www.xtentinc.com


'/>"/>
SOURCE XTENT
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Biomoda, Inc. Retains MicroCap Management, LLC as its Lead Corporate Communications and Broker Relations Firm.
2. National Stem Cell Holding, Inc. Posts Company and Financial Information on the OTCIQ and Has Retained New CFO and Counsel to File Registration Statement With SEC
3. China Pharma Holdings, Inc. Retains HC International, Inc. to Implement Investor Relations Program
4. Carrington Retains Milkie/Ferguson to Explore Financial Alternatives
5. NuRx Pharmaceuticals Retains Russo Partners for Investor Relations, Corporate Communications Counsel
6. Dragon retains leading investor relations firm
7. Interleukin Genetics Retains Top Life Science Communications Firms
8. SPO Medical Retains American Capital Ventures for Investor Relations Services
9. AMDL, Inc. Retains Strategic Growth International Inc. as its Global Investor Relations Advisor
10. CellCyte Genetics Retains InCap Group to Advise on Business Strategy and Financing
11. Insmed Retains RBC Capital Markets as Strategic Financial Advisor
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/18/2017)... ... January 18, 2017 , ... Thirty-six startup companies in University City ... Pennsylvania Department of Community and Economic Development in 2016 as part of the Keystone ... University City Keystone Innovation Zone and represent the highest number of awards to the ...
(Date:1/18/2017)...  HUYA Bioscience International, (HUYA), the leader in accelerating ... pharmaceutical innovations, announced today a strategic collaboration agreement with ... (referred to as CAS Innovation). The collaboration will focus ... scientists at CAS to meet the medical needs of ... first company to have recognized China,s ...
(Date:1/18/2017)... 2017 /PRNewswire/ - SQI Diagnostics Inc. (TSX-V: SQD; ... that develops and commercializes proprietary technologies and products ... today announced that Cameron Prange , President ... from its Board of Directors.  Mr. Prange,s resignation ... that have limited both his ability to act ...
(Date:1/17/2017)... (PRWEB) , ... January 17, 2017 , ... ... addition of Rheumatoid Factor (RF) to its VALIDATE® SP2 calibration verification / linearity ... in a human serum base. Each VALIDATE® SP2 kit is prepared using the ...
Breaking Biology Technology:
(Date:1/11/2017)... MOINES, Iowa , Jan. 11, 2017 ... industry first with the release of its patent-pending calibration ... quickly and reliably perform calibrations, securely upload data logs ... flexibility for the customer. "Fighting drunk driving ... only for the public at large, but also for ...
(Date:1/6/2017)... Calif. , Jan. 5, 2017  Delta ID ... its iris scanning technology for automotive at CESĀ® 2017. ... GNTX ) to demonstrate the use of iris ... identify and authenticate the driver in a car, and ... during the driving experience. Delta ID and ...
(Date:12/22/2016)... 2016  As part of its longstanding mission to improve ... company, recently released its latest children,s book, titled ... on the topics of inheritance and variation of traits that ... in elementary school classrooms in the US. ... Ariana Killoran , whose previous book with 23andMe, ...
Breaking Biology News(10 mins):